Loading...
Publication
O papel do liraglutido no tratamento da obesidade em crianças e adolescentes
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| Documento em Acesso Embargado até dia 16-01-2028. Tente solicitar cópia ao autor carregando no ficheiro | 725.21 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Introdução: Ao longo das últimas décadas houve um acréscimo das crianças e adolescentes com excesso de peso ou obesidade, o que tem trazido preocupações a nível mundial. A prevalência tem aumentado e tem provocado comorbilidades importantes, nomeadamente físicas, psicológicas, económicas e sociais, tanto a curto como a longo prazo. A obesidade é uma doença crónica, mas quando detetada atempadamente consegue ser tratada. A abordagem é limitada e multimodal enfatizando em primeira linha modificações de estilo de vida, contudo têm produzido efeitos pouco duradouros. Objetivos: O presente trabalho tem como objetivo analisar o tratamento da obesidade em crianças e adolescentes (idade entre os 6 e os 18 anos) com o liraglutido, e assim verificar se existe uma utilização segura e eficiente para estas faixas etárias deste fármaco, bem como os possíveis mecanismos pelos quais ele atua. Métodos: Para a elaboração desta monografia, procedeu-se à pesquisa de artigos na plataforma PubMed, Scopus e Web of Science, com as seguintes palavras-chave; “liraglutide”, “child”, “adolescent”, “obesity”, “Glucagon-Like Peptide 1”, e os seguintes operadores booleanos, “AND” e “OR”. Resultados: Foram analisados 8 artigos que abordavam o tratamento da obesidade usando o liraglutido nestas faixas etárias. Na generalidade, foram identificados resultados que traduzem redução do peso e IMC médio, resolução de complicações associadas, melhoria de sintomas relacionados com ansiedade e depressão, melhoria do perfil metabólico e cardiovascular. Discussão e Conclusões: Este trabalho permitiu observar que este fármaco, o liraglutido, é dentro dos fármacos desta classe o mais prescrito. Contudo, este trabalho apresentou várias limitações, nomeadamente o número reduzido de estudos, o tempo reduzido de administração deste fármaco ou a amostra pequena. A tolerância do paciente a este fármaco também foi determinante para a duração do tratamento, tendo em conta, maioritariamente efeitos gastrointestinais, causados. De maneira concisa, os estudos analisados oferecem resultados promissores, eficazes e seguros, onde o liraglutido apresenta um papel importante na redução de IMC e do peso corporal associado a um estilo de vida saudável, contudo, ainda há muitos parâmetros e consequências por compreender, sendo necessária mais investigação sobre o tema antes de uma conclusão. Assim sendo, atualmente ainda é difícil determinar a eficácia a longo prazo da injeção de liraglutido.
Introduction: Over the last few decades there has been an increase in the number of children and adolescents who are overweight or obese, which has caused worldwide concern. The prevalence has increased and has caused important comorbidities, including physical, psychological, economic and social, both in the short and long term. Obesity is a chronic disease, but when detected early it can be treated. The approach is limited and multimodal, emphasizing lifestyle changes in the first instance, but it has had little lasting effect. Aims: This paper aims to analyze the treatment of obesity in children and adolescents (aged between 6 and 18) with liraglutide, and thus verify whether there is a safe and efficient use for these age groups of this drug, as well as the possible mechanisms by which it acts. Methods: To prepare this monograph, we searched for articles on the PubMed, Scopus and Web of Science platforms, using the following keywords; “liraglutide”, “child”, “adolescent”, “obesity”, “Glucagon-Like Peptide 1”, and the following boolean operators, “AND” and “OR”. Results: Eight articles were analyzed which dealt with the treatment of obesity using liraglutide in these age groups. In general, results were identified that reflected a reduction in weight and average BMI, resolution of associated complications, improvement in symptoms related to anxiety and depression, and improvement in the metabolic and cardiovascular profile. Discussion and Conclusions: This study showed that this drug, liraglutide, is the most widely prescribed drug in this class. However, this study had a number of limitations, including the small number of studies, the short administration time of this drug and the small sample size. The patient's tolerance to this drug was also a determining factor in the duration of treatment, taking into account the gastrointestinal effects mostly caused. In summary, the studies analyzed offer promising, effective and safe results, where liraglutide plays an important role in reducing BMI and body weight associated with a healthy lifestyle, however, there are still many parameters and consequences to be understood, and more research is needed on the subject before a conclusion can be drawn. Thus, it is currently still difficult to determine the long-term efficacy of liraglutide injection.
Introduction: Over the last few decades there has been an increase in the number of children and adolescents who are overweight or obese, which has caused worldwide concern. The prevalence has increased and has caused important comorbidities, including physical, psychological, economic and social, both in the short and long term. Obesity is a chronic disease, but when detected early it can be treated. The approach is limited and multimodal, emphasizing lifestyle changes in the first instance, but it has had little lasting effect. Aims: This paper aims to analyze the treatment of obesity in children and adolescents (aged between 6 and 18) with liraglutide, and thus verify whether there is a safe and efficient use for these age groups of this drug, as well as the possible mechanisms by which it acts. Methods: To prepare this monograph, we searched for articles on the PubMed, Scopus and Web of Science platforms, using the following keywords; “liraglutide”, “child”, “adolescent”, “obesity”, “Glucagon-Like Peptide 1”, and the following boolean operators, “AND” and “OR”. Results: Eight articles were analyzed which dealt with the treatment of obesity using liraglutide in these age groups. In general, results were identified that reflected a reduction in weight and average BMI, resolution of associated complications, improvement in symptoms related to anxiety and depression, and improvement in the metabolic and cardiovascular profile. Discussion and Conclusions: This study showed that this drug, liraglutide, is the most widely prescribed drug in this class. However, this study had a number of limitations, including the small number of studies, the short administration time of this drug and the small sample size. The patient's tolerance to this drug was also a determining factor in the duration of treatment, taking into account the gastrointestinal effects mostly caused. In summary, the studies analyzed offer promising, effective and safe results, where liraglutide plays an important role in reducing BMI and body weight associated with a healthy lifestyle, however, there are still many parameters and consequences to be understood, and more research is needed on the subject before a conclusion can be drawn. Thus, it is currently still difficult to determine the long-term efficacy of liraglutide injection.
Description
Keywords
Liraglutido Criança Adolescente Obesidade Glucagon-Like Peptide 1 Liraglutide Child Adolescent Obesity